Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label, Unblinded, Single Dose Study for Evaluating the Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients

NCT01374165 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.

NCT NCT01374165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01374165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label, Unblinded, Single Dose Study for Evaluating the Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
Lead sponsor
Prolong Pharmaceuticals
Phase
Observational
Overall status
Withdrawn
Start date
January 31, 2015
Completion date
January 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease